A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2016
At a glance
- Drugs Tasquinimod (Primary)
- Indications Fallopian tube cancer; Gastric cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms Umbrella
- Sponsors Ipsen
- 13 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database record.
- 31 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 11 Feb 2015 According to an Active Biotech media release, results from this study are expected in 2015.